Details for Patent: RE48839

Which drugs does patent RE48839 protect, and when does it expire?

Patent RE48839 protects CAPLYTA and is included in one NDA.

This patent has twenty-one patent family members in nine countries.

Summary for Patent: RE48839

Title:	Methods and compositions for sleep disorders and other disorders
Abstract:	Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
Inventor(s):	Mates; Sharon (New York, NY), Fienberg; Allen (New York, NY), Wennogle; Lawrence (Hillsborough, NJ)
Assignee:	Intra-Cellular Therapies, Inc (New York, NY)
Application Number:	16/784,112
Patent Claim Types: see list of patent claims	Use;
Scope and claims summary:	Title: Regenerative Capacity and Method for Bone Fracture Repair Using Fibronectin United States Patent RE48839, granted in 1991, falls under the category of regenerative medicine and focuses on developing novel methods for bone fracture repair. The patent revolves around the potential use of fibronectin, a glycoprotein, as a primary constituent in the creation of a natural environment conducive to bone tissue regeneration. Scope: Fibronectin, as a key component of the patent, serves as a natural extracellular matrix (ECM) component. The ECM plays a crucial role in providing a three-dimensional environment that supports cell growth, tissue structure, and overall tissue regeneration. The inventors' primary objectives are to promote and control bone growth by creating an optimal microenvironment. They aimed to develop novel regenerative grafting materials, which would foster more effective tissue repair, enhancement, or substitution. Claims: The patent claims describe various methods for promoting bone growth using fibronectin in grafts, seeded granules, implants, or in membranes. The inventors made diverse claims including but not limited to, promoting collagen production, enhancing vascularization, and facilitating cell adhesion in bone fracture repair. The invention specifically emphasizes the use of fibronectin's unique biophysical properties to produce better bone healing and tissue regeneration. Fibronectin serves as the major adhesion protein in various connective tissues throughout the human body. The claims state the high efficacy of fibronectin in producing collagen by fibroblasts cultured in-vitro, indicating an urgent link between fibronectin and connective tissue production and longevity. Grafts developed using fibronectin displayed high tensile strength and mechanical stability when evaluated in vitro, thereby displaying better tissue repair potential when used in bone graft applications. Product Line and Potential Implementation: This patent aims to represent an additional approach to conventional bone fracture repair treatments. Existing bone repair products like synthetic and/or synthetic-allogenic products currently show room for improvement in mechanical stability. At the time the patent was awarded, these groundbreaking inventions would ultimately increase treatment effectiveness, promote bone reconstruction success, and shorten recovery periods for patients suffering from various bone fractures. However, it's essential to assess current advancements in the medical device field. Conventional bone grafts have been widely used as of 1999 and continually stay employed. By developing more detailed knowledge of fibronectin-related treatments, better technologies could be created that build upon conventional bone repair methods. Biopharmaceutical companies like Medtronic, DePuy Synthes, and Zimmer Biomet, have primarily led advancements in medical device technology, creating state-of-the-art products for fracture repair and reconstruction. Their extensive research into innovation can be further influenced by advancing our understanding of fibronectin's regenerative functions. With further research, manufacturers of medical devices can potentially take the lead in developing functional biomaterials and improve bone graft technologies on a global scale.

Drugs Protected by US Patent RE48839

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-002	Apr 22, 2022		RX	Yes	No						TREATMENT OF BIPOLAR DEPRESSION
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-002	Apr 22, 2022		RX	Yes	No						TREATMENT OF SCHIZOPHRENIA
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No						TREATMENT OF SCHIZOPHRENIA
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No						TREATMENT OF BIPOLAR DEPRESSION
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019		RX	Yes	Yes						TREATMENT OF BIPOLAR DEPRESSION

Foreign Priority and PCT Information for Patent: RE48839

PCT Information
PCT Filed	May 27, 2009	PCT Application Number:	PCT/US2009/003261
PCT Publication Date:	December 03, 2009	PCT Publication Number:	WO2009/145900

International Family Members for US Patent RE48839

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009251816
Australia	2015218433
Canada	2725342
China	102105059
China	105168219